The interactions of intercellular adhesion molecules-1 and -3 (ICAM-1 and ICAM-3) with lymphocyte functionassociated antigen-1 (LFA-1) have been characterized and compared on the molecular and cellular level. Enzyme-linked immunosorbent-based molecular assays have been utilized to calculate the binding affinities of soluble ICAM-1 (sICAM-1) and soluble ICAM-3 (sICAM-3) for LFA-1. Consistent with previously published data, we found that sICAM-1 binds to LFA-1 with an affinity of ϳ60 nM. In contrast, sICAM-3 binds to LFA-1 with an affinity ϳ9 times weaker (ϳ550 nM). Both sICAM-1 and sICAM-3 require divalent cations for binding. Specifically, both Mg 2؉ and Mn 2؉ support high affinity adhesion, although interestingly, high concentrations of Ca 2؉ decrease the affinity of each molecule for LFA-1 substantially. Furthermore, a panel of anti-LFA-1 monoclonal antibodies were characterized for their ability to block sICAM-1 and sICAM-3/LFA-1 interactions in molecular and cellular assays to help distinguish binding sites on LFA-1 for both molecules. Finally, molecular and cellular competition experiments demonstrate that sICAM-1 and sICAM-3 compete with each other for binding to LFA-1. The above data demonstrate that sICAM-1 and sICAM-3 share a common binding site or an overlapping binding site on LFA-1 and that the apparent differences in binding sites can be attributed to different affinities of sICAM-1 and sICAM-3 for LFA-1.
ICAM-1 is an inducible molecule that is up-regulated by inflammatory cytokines on endothelium, leukocytes, and multiple other cell types (1, 2) , whereas ICAM-3 is constitutively expressed on leukocytes and absent from endothelium and most other cell types under normal conditions (5, 9, 10) . Since ICAM-3 is constitutively expressed at high levels on unactivated T-cells and antigen presenting cells and has been shown to mediate T-cell activation in vitro (3, (5) (6) (7) 12) , it is believed to primarily play a role in lymphocyte activation during antigen presentation. In fact, ICAM-1 and ICAM-3 appear to function synergistically and/or additively with each other as demonstrated by the ability of monoclonal antibodies (mAb) to ICAM-1 and ICAM-3 to have synergistic or additive effects in vitro in inhibiting the mixed lymphocyte reaction, antigen/ mitogen-induced proliferation, and homotypic aggregation assays (3, 6, 7, (12) (13) (14) (15) .
In terms of the binding characteristics of ICAM-1 and ICAM-3 for LFA-1, cellular assays have demonstrated that ICAM-1/LFA-1 and ICAM-3/LFA-1 interactions have similar divalent cation and temperature dependences (3, 16) . Correlation of surface expression measurements and the binding of T-cells and cell lines to purified LFA-1 suggest that ICAM-1 exhibits a higher affinity for LFA-1 than ICAM-3 (5) .
Mutagenesis studies on LFA-1 have provided evidence that ICAM-1 and ICAM-3 might bind to distinct sites defined within the inserted (I) domain of CD11a (17, 18) . This concept has been further supported by the observation that certain mAbs to LFA-1 preferentially inhibit the binding of leukocytes to purified ICAM-3 but not to ICAM-1 (18 -20) . Also, a peptide that maps to the amino terminus of the I domain has been described that inhibits binding of T-cells to ICAM-3 but not ICAM-1 (17) .
In this paper, we characterize the interactions of ICAM-1 and ICAM-3 with LFA-1 on the molecular level to understand better the structure and function of the LFA-1/ICAM interaction. Furthermore, we mapped ICAM-1 and ICAM-3 interactions with LFA-1 using mAb and competitive binding assays to determine whether or not ICAM-1 and ICAM-3 share a common binding site on LFA-1.
EXPERIMENTAL PROCEDURES
Antibodies-R6.5 (anti-ICAM-1 (21)), R7.1/R3.1 (anti-CD11a (22, 23) ), and R15.7/R3.3 (anti-CD18 (24, 25)) were previously described. CBR-IC3/1 and CBR-IC3/2 (anti-ICAM-3), TS 1/18 (anti-CD18), TS 1/22, and TS 2/4 (anti-CD11a) were kind gifts from Dr. T. A. Springer. MEM-83 (anti-CD11a) was purchased from Monosan (The Netherlands). YTH81.5 (anti-CD11a) was purchased from Serotec (Washington, D.C.). 25.3.1 (anti-CD11a) was purchased from Immunotech (France). mAb 38 (antiCD11a) and CLB-LFA-1/2 (anti-CD11a) were purchased from RDI, Inc. (Flanders, NJ). G-25.2 (anti-CD11a) was purchased from Becton Dickinson (San Jose, CA). IB4 (anti-CD18) was purchased from Ancell (Bayport, MN). MHM 23 (anti-CD18) and MHM 24 (anti-CD11a) were * The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. This paper is dedicated to Enza and Joey. § To whom correspondence should be addressed: Dept. of Immunological Diseases, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Rd., P.O. Box 368, Ridgefield, CT 06877. Tel.: 203-791-6252; Fax: 203-791-6196; E-mail: jwoska@bi-pharm.com. 1 The abbreviations used are: ICAM, intercellular adhesion molecules; sICAM, soluble ICAM; LFA-1, lymphocyte function-associated antigen-1; ELISA, enzyme-linked immunosorbent assay; PMA, phorbol 12-myristate 13-acetate; mAb, monoclonal antibody. purchased from Biomeda (Foster City, CA).
Production of a Soluble Form of ICAM-3-Full-length ICAM-3 cDNA in the CDM8 vector was a kind gift of Dr. T. A. Springer. Using the polymerase chain reaction, a soluble form of ICAM-3 was constructed by engineering a stop codon at the putative boundary of domain 5 and the transmembrane domain. Polymerase chain reaction generated a cDNA encoding a mature, soluble form of ICAM-3, consisting of 456 amino acid residues. The cDNA was subsequently cloned into the EcoRI site of the pEE12 vector and expressed in NSO-1 mouse myeloma cells using the Celltech glutamine synthetase gene amplification system (Celltech, Ltd., Berkshire, UK). Briefly, 40 g of linearized plasmid DNA was introduced into 1 ϫ 10 7 NSO-1 cells by electroporation. After dilution in nonselective media and incubation at 37°C for 24 h, selection media without glutamine was added to each well. After 18 -25 days posttransfection, wells were screened for the production of sICAM-3 using a sICAM-3 detection ELISA (BioSource International, Camarillo, CA). The highest expressing recombinant was chosen for scale-up and produced sICAM-3 at ϳ150 g/ml. After scale-up, sICAM-3 was purified using conventional immunoaffinity chromatography utilizing the mAb, CBR-IC3/1, the same mAb that was used to characterize and clone ICAM-3 (5, 8) . Soluble ICAM-3 was deglycosylated under nondenaturing conditions using recombinant N-glycosidase F (Boehringer Mannheim, GmbH, Germany) according to the instructions recommended by the manufacturer. Detergent and denaturing reagent were omitted from the reaction to retain the binding activity of the molecule. Deglycosylation of the nondenatured sample was monitored by SDS-polyacrylamide gel electrophoresis and compared with a sample which contained SDS and detergent.
Soluble ICAM-1 Production-An unlabeled, soluble ICAM-1 (sICAM-1) and a biotinylated, soluble form of ICAM-1 (CB-sICAM-1) were constructed and purified as described previously (26, 27) .
LFA-1 Purification-Micellar LFA-1 was purified from SKW-3 cells utilizing the protocol published by Dustin et al. (28) and, as described previously, yielding an active form of LFA-1 capable of binding ICAMs with high affinity (26) .
SDS-Polyacrylamide Gel Electrophoresis/Western Blots-The purity and structure of sICAM-3 was confirmed by Western blotting. Approximately 1 g per lane of sICAM-3 or sICAM-1 were electrophoresed on a 4 -12% Tris/glycine gel (NOVEX, San Diego, CA) under reducing and denaturing conditions. Proteins were transferred to nitrocellulose and blotted with rabbit polyclonal serum raised against a domain 4 peptide of ICAM-3 or from polyclonal serum raised against sICAM-1. The proteins were then visualized with a goat anti-rabbit Ig alkaline phosphatase conjugate and 5-bromo-4-chloro-3-indolyl phosphate/nitro blue tetrazolium pre-mixed substrate solution (Zymed, South San Francisco). sICAM-3 appears as a broad band with an approximate molecular mass of 90 -100 kDa, characteristic of a highly glycosylated soluble form of ICAM-3 (see Fig. 6b, 3rd lane) . A soluble form of ICAM-1 was electrophoresed giving a slightly lower apparent molecular mass (see Fig. 6b , 2nd lane).
Direct Binding and Competitive Binding Assays-Aliquots (50 l) of purified LFA-1, at a concentration of ϳ5-8 g/ml in assay buffer (AB, Dulbecco's phosphate-buffered saline (Life Technologies, Inc.) ϩ 2 mM MgCl 2 and 0.1 mM phenylmethylsulfonyl fluoride), diluted below the critical micelle concentration for n-octylglucoside, were allowed to adsorb to wells of a maxisorp microtiter plate (Nunc, Naperville, IL) for 1 h at room temperature. Plates were then washed and blocked for 30 min at 37°C in 2% bovine serum albumin/AB. For sICAM-3 direct binding assays, purified sICAM-3 in AB was serially diluted 1:2 across the plate in duplicate or triplicate and allowed to incubate at 37°C for 1 h. After incubation, the plates were washed with AB, and 50 l of rabbit polyclonal serum raised against a domain 4 peptide diluted 1:100 in 1% bovine serum albumin/AB was added to each well and incubated for 20 min at 37°C. After washing again with AB, a 1:4000 dilution of goat anti-rabbit Ig horseradish peroxidase conjugate (Zymed) was added to each well and incubated at 37°C for 15-20 min. After another wash step, 200 l of 2,2Ј-Azino-bis(3-ethylbenzthiazoline-6-sulfonic acid) diammonium salt substrate (Zymed) was added to each well and incubated at 37°C for 20 min. The absorbance was then measured with a Molecular Devices Thermomax plate reader (Menlo Park, CA) at 405 nm. For all divalent cation experiments, assays were performed in the presence of either 1 mM Ca 2ϩ or 0.4 mM Mn 2ϩ in the AB replacing the 2 mM Mg 2ϩ as needed throughout the assay, including washes. Direct assays involving biotinylated sICAM-1 and a horseradish peroxidase/ streptavidin reporter were performed as described (26) . For competitive binding assays, serially diluted competitors (sICAM-1, sICAM-3, mAbs) were added to an equal volume of sICAM-3 or biotinylated sICAM-1 at a constant concentration, and the assays were continued as described above and as described previously (26) .
Cellular Adhesion Assays-Purified sICAM-3 or sICAM-1 were plated at 10 -40 g/ml (50 l/well in duplicate) on Linbro EIA II 96-well plates (Flow Laboratories, McLean, VA) and allowed to adsorb for 1 h at room temperature. Purified LFA-1 was plated as above, but at concentrations ranging from 1 to 2 g/ml. The plates were then washed and blocked with 2% bovine serum albumin/AB for 1 h at 37°C. Fifty l of washed SKW-3 cells Ϯ 50 ng/ml phorbol 12-myristate 13-acetate (PMA) (Sigma) at 2 ϫ 10 6 cells/ml in complete media (RPMI, 15% fetal calf serum, 10 mM HEPES, Life Technologies, Inc.) were then added to the blocked wells (purified sICAM-1 and sICAM-3 were allowed to preincubate with blocked LFA-1 for 15 min at room temperature before addition of cells). The test samples (mAb at various concentrations) in AB were added to the wells in an equal volume and allowed to incubate at 37°C for 1 h. Unbound cells were removed by 4 washes with warm RPMI using a multichannel pipettor. Bound cells were then quantified using 3-(4,5-dimethyl thiazol-2-yl)-2,5-diphenyl tetrazolium bromide, thiazolyl blue reagent. Briefly, 10 l of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide, thiazolyl blue (Sigma) reagent (5 mg/ml in RPMI) was added to each well and incubated at 37°C for 3-4 h. After incubation, crystals were solubilized in 0.04 N HCl in isopropyl alcohol, and absorbance was measured at 570 nm.
Computational Analyses-All data were analyzed using the SAS statistical software system, version 6.11 (SAS Institute, Cary, NC). ASCII data files containing absorbance measurements from ELISA experiments were converted into SAS data sets. Using the NLIN procedure, data analyses were performed by applying ordinary nonlinear least squares regression techniques to the selected model (see Ref. 26) , using the Marquardt-Levenberg minimization method (35) .
RESULTS
An ELISA-based assay was utilized to measure the binding interaction between sICAM-1 or sICAM-3 and immunopurified, immobilized LFA-1. Fig. 1 shows two representative experiments, demonstrating the binding of sICAM-3 and biotinylated sICAM-1 to LFA-1. Previous results have demonstrated that biotinylation of sICAM-1 does not affect its affinity for LFA-1 (26) . Fig. 1a shows a representative sICAM-3 direct binding assay. As the concentration of sICAM-3 is increased in the assay, the absorbance measured at 405 nm increases producing a typical sigmoidal shaped curve. These data were analyzed with the equilibrium model for direct binding (see " Ma- the midpoint of the curve for sICAM-3 is shifted to higher concentrations. Purified sICAM-3 was then tested for its ability to effectively support the binding of an LFA-1 bearing cell line. Fig. 2a shows the binding of the T-cell lymphoma SKW-3 to immobilized sICAM-3. Treatment of the cells with PMA (50 ng/ml) in the presence of divalent cations resulted in a 2-fold increase in binding presumably due to an increase in avidity resulting from integrin clustering and a change in the activation state of LFA-1 from a low to high affinity state (29 -33) . The binding of SKW-3 cells to immobilized sICAM-3 was inhibited by the blocking anti-CD11a mAb, (R3.1). Both the anti-ICAM-3 mAbs (CBR-IC3/1 and CBR-IC3/2) when used together effectively decreased the number of cells bound to purified sICAM-3 by ϳ70%. The combination of these antibodies is needed to block the adhesion of LFA-1 bearing cells to purified sICAM-3, similar to what has been demonstrated by de Fougerolles et al. (3) . The reason for this phenomenon is unknown, but it has been speculated that neither CBR-IC3/1 nor CBR-IC3/2 map to the binding site on ICAM-3 for LFA-1 and therefore a combination of both mAbs is needed to sterically hinder the binding of ICAM-3 to LFA-1. These observations demonstrate the specificity of the sICAM-3/LFA-1 interaction. The binding of SKW-3 cells to immobilized sICAM-1 was also characterized (see Fig.  2b ). A 2-3-fold increase in binding was observed when cells were treated with PMA. Both a blocking anti-ICAM-1 (R6.5) and the blocking anti-CD11a mAb R3.1 inhibited binding of the SKW-3 cells to immobilized sICAM-1, demonstrating the specificity of the sICAM-1/LFA-1 interaction under the same assay conditions.
The divalent cation requirements for binding of both sICAM-3 and sICAM-1 to LFA-1 were then characterized on the molecular level. On the cellular level, these requirements have been well characterized for LFA-1-mediated binding to both ICAM-1 (16, 34) and ICAM-3 (3) and have shown that cellular LFA-1 requires Mg 2ϩ or Mn 2ϩ to be functional in binding ICAM-1 or ICAM-3. Previous direct binding experiments (Fig. 1, a and b) were performed in the presence of Mg Fig. 3b) . Both values are similar to the binding observed for sICAM-3 and sICAM-1 in the presence of Mg 2ϩ . When each ELISA was performed in the presence of Ca 2ϩ , replacing the Mg 2ϩ , binding was observed but only at very high concentrations of sICAM-3 and sICAM-1 (Ͼ100 M). Due to the limits of protein solubility, a complete curve could not be generated and a K d could not be calculated. It can, however, be estimated that the affinities of sICAM-1 and sICAM-3 for LFA-1 in the presence of high concentrations of Ca 2ϩ are at least 100-fold weaker than their respective affinities calculated in the presence of Mg 2ϩ or Mn 2ϩ . These data are consistent with the observations that have been characterized for both interactions on the cellular level.
To distinguish whether ICAM-3 or ICAM-1 has unique binding sites on LFA-1, a panel of anti-CD11a and anti-CD18 mAbs were evaluated in molecular binding assays. Fig. 4, a and b, shows the inhibitory profiles of these mAbs in the sICAM-3/ LFA-1 and sICAM-1/LFA-1 molecular binding assays, respectively (each ICAM was used at 3 ϫ its respective K d , normalizing their unequal affinities). A similar inhibition profile can be seen with both ICAMs. The one exception is MEM-83, which gives slight inhibition in the sICAM-3 assay and none in the sICAM-1 assay. Two previous reports have shown that MEM-83 and YTH81.5, which map to the I domain of CD11a, selectively inhibit ICAM-3/LFA-1-mediated adhesion and not ICAM-1/LFA-1-mediated adhesion (18 -20) . In this report, YTH81.5 inhibits both sICAM-1 and sICAM-3 binding to immobilized LFA-1 in a dose-dependent manner (see Fig. 5a ), whereas MEM-83 only shows activity in the sICAM-3 assay (see Fig. 5b ). In cellular assays involving either sICAM-3 or sICAM-1, neither mAb showed any activity up to 300 and 50 g/ml of YTH81.5 and MEM-83, respectively (data not shown).
Since ICAM-3 is the most highly glycosylated member of the ICAMs with 15 putative N-linked glycosylation sites within the protein (8 -10), the role of glycosylation in the binding of ICAM-3 to LFA-1 was evaluated using molecular assays. Deglycosylation of sICAM-3 was performed with recombinant Nglycosidase F in the presence or absence of denaturing agents and detergent. In Fig. 6a , samples of sICAM-3 (de-glycosylated in the presence (lane 3) or absence (lane 2) of SDS/detergent) were electrophoresed and blotted with polyclonal serum directed against domain 4 of sICAM-3. As can be seen, both samples were digested to their predicted polypeptide backbone molecular weight (ϳ50,000) compared with the undigested protein (see Fig. 6b, 3rd lane) . Direct binding ELISAs with the . Nonlinear regression analysis using the model given gave a K d ϭ 124(Ϯ13) nM, in which the number in parentheses is the S.E. nondenatured de-glycosylated form of sICAM-3 were then performed to determine if the loss of sugars affected the affinity of the molecule for LFA-1. The K d of the interaction between de-glycosylated sICAM-3 and LFA-1 was calculated to be 609 (Ϯ90) (see representative experiment, Fig. 6c, n ϭ 3) , quite similar to the fully glycosylated form. These data show that the binding event is not affected by the presence or absence of carbohydrates.
Since the mAb data does not clearly distinguish separate binding sites for each molecule, competitive molecular binding assays were performed with unlabeled sICAM-1 or sICAM-3. Fig. 7 shows curves from two representative experiments where unlabeled sICAM-1 or sICAM-3 compete with biotinylated sICAM-1 in solution for immobilized LFA-1. Titrating the unlabeled sICAMs (holding the concentration of biotinylated sICAM-1 constant) results in a decrease in signal due to decreased biotinylated sICAM-1 binding. This decrease is due to competition between unlabeled sICAM-1 or sICAM-3 and the biotinylated sICAM-1 for LFA-1. The data in Fig. 7 were analyzed using the equilibrium competitive binding model given in the Appendix of Ref. 26 . K d values for competitive binding of unlabeled sICAM-1 and sICAM-3 were determined to be 77 (Ϯ20) nM (n ϭ 4) and 724 (Ϯ105) nM (n ϭ 4), respectively. These results show a 9 -10-fold difference in affinity between the two ICAMs (see Fig. 7 ) in agreement with the K d values determined in the direct binding experiments (see Fig. 1 ) and also clearly demonstrate that both ICAMs compete with each other in solution for LFA-1.
To further characterize this phenomenon, a cellular assay was performed utilizing SKW3 cells, a T-cell lymphoma that expresses mostly ICAM-2 and ICAM-3. SKW3 cells readily adhere to purified LFA-1, immobilized on a microtiter plate. The anti-LFA-1 mAb, R3.1, blocks the cells from binding with an IC 50 of about 30 nM (see Fig. 8 ). Both sICAM-1 and sICAM-3 also block the binding of SKW3 cells to purified LFA-1. sICAM-1 blocks with an IC 50 of about 300 -400 nM and sICAM-3 blocks with an IC 50 of about 4 -5 M. One can observe about a 10-fold difference between the ICAMs in their ability to block cell binding, characteristic of their affinity differences.
DISCUSSION
In this paper, the binding affinities of sICAM-3 and sICAM-1 for LFA-1 have been determined using results obtained from molecular based ELISA assays. The affinity of the sICAM-3/ LFA-1 interaction is approximately 9 -10 times weaker than the sICAM-1/LFA-1 interaction (see Fig. 1 ). The relative affin- ities obtained in the molecular assays are consistent with previously reported cellular data (5) and with data shown in Fig. 8 using cell-based assays.
It has been suggested by many groups that due to its high constitutive expression on various leukocytes, ICAM-3 may be responsible for the initial phases of the immune response (3, (5) (6) (7) (8) (9) (10) (11) (12) . One can envision LFA-1/ICAM-3 interactions initiating the original T-lymphocyte/antigen presenting cell contact during the primary interactions in an immune response. Following this initial contact, as ICAM-1 expression is induced due to inflammatory stimuli, the LFA-1/ICAM-1 interactions begin to dominate over the LFA-1/ICAM-3 interactions due to the higher affinity of ICAM-1 over ICAM-3 for LFA-1. Since ICAM-1 is expressed on target cells and at sites of inflammation, these data suggest that ICAM-3/LFA-1 interactions mediate the initial CD18-dependent leukocyte/leukocyte interaction and that ICAM-1/LFA-1 interactions mediate the subsequent leukocyte/leukocyte and leukocyte/target cell interactions.
The divalent cation dependences of sICAM-1/LFA-1 and sICAM-3/LFA-1 interactions in the molecular assays have confirmed what has previously been demonstrated at the cellular level (5, 16, 34 thereby decreasing the affinity of LFA-1 for both ICAM-1 or ICAM-3. These data strengthen the argument that the molecular assays reflect what is seen at the cellular level and provide evidence that LFA-1 binding to ICAM-1 or ICAM-3 occurs at similar sites. The role of glycosylation in the binding of ICAM-3 to LFA-1 was determined since a deglycosylated form of ICAM-1 has been shown to bind LFA-1 with approximately the same affinity as the native form and bind MAC-1 with a higher affinity (36). Similar to ICAM-1/LFA-1 interactions, we found that ICAM-3 bound to LFA-1 with equal affinity regardless of whether it was deglycosylated or not. However, it remains to be seen if the deglycosylation will confer the ability to bind to MAC-1 upon ICAM-3 or alter its ability to bind ␣ D ␤ 2 . Various anti-CD11a and anti-CD18 mAbs were tested in molecular assays to help distinguish binding sites for ICAM-1 and ICAM-3 on LFA-1. Most of the mAbs displayed similar inhibitory profiles in sICAM-1/LFA-1-dependent and sICAM-3/ LFA-1-dependent molecular and cellular assays (see Figs. 2, 4 , and 5). The one exception was MEM-83, an anti-CD11a mAb that maps to the I domain, which showed slight inhibition of sICAM-3 binding to LFA-1, but not sICAM-1 binding to LFA-1 in a molecular assay. These data are consistent with that reported by Binnerts et al. (18, 19) who have shown that MEM-83, which induces high affinity adhesion between LFA-1 and ICAM-1, blocks the binding of T-cells to ICAM-3. On the other hand, we were unable to see any inhibition of LFA-1-bearing cells binding to immobilized sICAM-3 or sICAM-1 at concentrations up to 50 g/ml. Another mAb, YTH81.5, which has also been shown to be a selective inhibitor of ICAM-3/LFA-1 (but not ICAM-1/LFA-1 interactions in cell assays) (18, 20) was also tested in molecular and cellular assays here. We found YTH81.5 to inhibit both sICAM-3 and sICAM-1 binding to LFA-1 in the molecular assays. Also, like MEM-83, YTH81.5 had no activity in cellular assays. Although the reason(s) for the discrepancy between the results reported here and the previous reports in the cell-based assays is not clear, certainly the stringency of the assays dictated by the degree of washing of the plates, the amount of functionally active LFA-1 on the adhering cells, and the amount and quality of the expressed ICAM-1 and ICAM-3 may play a role. In terms of MEM-83 inhibiting ICAM-3/LFA-1 interactions but not ICAM-1/LFA-1 interactions, it is conceivable that MEM-83 does not bind to either the ICAM-1 or ICAM-3 binding site and the antibody sterically hinders the binding of only ICAM-3 to LFA-1 due to different protein structure in domains not directly involved in the binding site. ICAM-3 and ICAM-1 share an overall amino acid identity of only 50% and lower than 40% in several domains, which could account for the differences in protein structure where MEM-83 binding to LFA-1 may interfere with ICAM-3 but not ICAM-1. Molecular and cellular competition experiments presented herein clearly demonstrate that sICAM-1 and sICAM-3 compete with biotinylated sICAM-1 ( Fig. 7) and membrane-bound ICAM-1 and -3 ( Fig. 8 ) in solution for immobilized LFA-1, and also show the characteristic affinity difference between the two ICAMs for LFA-1. Furthermore, in the cellular experiments, sICAM-1 and sICAM-3 were also observed to compete with ICAM-2 present on the surface of the SKW-3 cells. This would suggest that ICAM-1, -2, and -3 may share a common binding site on LFA-1.
Further support that ICAM-1 and ICAM-3 bind to the same site within LFA-1 comes from a report by Staunton et al. (37) who have demonstrated that amino acid residues Glu-34 and (17) . Mutational analysis of the I domain of CD11a suggested that the amino-terminal region was responsible for ICAM-3 but not ICAM-1 binding. More specifically, Lys-127, Asn-129, and Asp-137 were critical for binding to ICAM-3. Interestingly, although transfected 293 cells containing these mutants showed a dramatic decrease in binding to ICAM-3, there was some inhibition of binding to ICAM-1. In the same report, a peptide that maps to the amino-terminal region of the I domain inhibited binding of LFA-1 expressing T-cells to immobilized ICAM-3 but not ICAM-1. There was, however, some inhibition of cell binding to ICAM-1, about 25% at 100 g/ml compared with 90% for ICAM-3 at the same dose. The same I domain peptide showed preferential inhibition of ICAM-3-mediated co-stimulation of peripheral blood lymphocytes but not ICAM-1-mediated co-stimulation. However, although the peptide displayed ϳ80% inhibition in the ICAM-3-mediated assay, it did show ϳ30 -40% inhibition in the ICAM-1-mediated assay. It is conceivable that the reason for the greater inhibitory effect of the peptide in ICAM-3-mediated adhesion to LFA-1 may be explained by the greater affinity of LFA-1 for ICAM-1, rather than the peptide inhibiting an ICAM-3-binding site but not an ICAM-1-binding site. In the former case, more peptide would be required to prevent LFA-1 bearing cells from adhering to ICAM-1 versus adhering to ICAM-3.
Although much of the work described above and in this paper focuses on the role of the I domain of CD11a in the ICAM-1 and ICAM-3 binding events, other residues defined within CD11a and CD18 appear to be important for ligand binding (43, 44) . These residues may define the differences in binding affinity and differentiate the roles of the different ICAMs in immune and inflammatory responses.
